Characterization of human gastric adenocarcinoma cell lines established from peritoneal ascites by Mytar, Bożenna et al.
ONCOLOGY LETTERS  15:  4849-4858,  2018
Abstract. The three cell lines, designated as gastric cancer 
(GC)1401, GC1415 and GC1436 were derived from peritoneal 
effusions from patients with gastric adenocarcinoma. Cell 
lines were established in tissue culture and in immunodefi-
cient, non-obese diabetic/severe combined immunodeficiency 
(NOD/SCID) mice. All cell lines were cultured in Dulbecco's 
modified Eagle's medium supplemented with 5% fetal bovine 
serum. These cell lines were grown as an adherent monolayer 
with doubling time ranging between 25 h (GC1436 cell line) 
and 30‑34 h (GC1401 and GC1415, respectively). All cells 
showed morphological features of epithelial-like cells, forming 
sheets of polygonal cells. Chromosomal analysis showed that 
the modal numbers ranged from 52 (GC1401), 51-56 (GC1415) 
and 106 (GC1436). High heterogeneity, resulting from several 
structural and numerical chromosomal abnormalities were 
evident in all cell lines. The surface marker expression 
suggested a tumor origin of the cells, and indicated the intes-
tinal phenotype of a GC (CD10+, MUC1). All three cell lines 
were tumorigenic but not metastatic, in vivo, in NOD/SCID 
mice. The lack of metastatic potential was suggested by the 
lack of aldehyde dehydrogenase 1A1 activity. In conclusion, 
these newly established GC cell lines widen the feasibility of 
the functional studies on biology of GC as well as drug testing 
for potential therapeutic purposes.
Introduction
Gastric cancer (GC) is the fifth most common malignancy 
in the world and the third in cancer-related death (1). One of 
the reasons behind high mortality is that patients at the time 
of diagnosis are usually at an advanced tumor stage, hence 
the need for new, more effective diagnostic and therapeutic 
approaches is urgent. Also, despite different therapies (surgery, 
chemotherapy, targeted therapy) the prognosis for patients is 
still poor (2). Among others, the reason for this poor prog-
nosis may lie in the biological heterogeneity of cancer cells, 
comprising their morphology and, more importantly, their 
functionality (3). Established tumor cancer cell lines are a 
very useful tool for studying cancer cell biology, heterogeneity 
or sensitivity to different drugs and therapies. A comprehen-
sive collection of well‑described cell lines should reflect the 
diversity of GC and provide adequate models for its study. Up 
to date, just a few GC cell lines are available, most of them 
being established from Asian patients (4-6), where this type of 
cancer is most prevalent.
In the present study we characterize three, new cell lines 
established from ascitic fluids of Caucasian patients with GC. 
The karyotype (by conventional G‑banding) of these cells, 
their phenotype [including tumor‑associated antigens (TAA) 
such as c-Met, Her-2/neu, Tag72, EMA, Epithelial Antigen and 
EMMPRIN], mRNA expression profile (Her‑2/neu, MAGE‑1) 
and growth in immunodeficient mice are presented. In addi-
tion, the expression and activity of aldehyde dehydrogenase 
(ALDH) isoforms relevant to metastatic potential of cancer 
cells are documented (7-11).
In conclusion, the presented data widens the current 
knowledge on GC cells and provides a liable laboratory model 
for anticancer drug testing and tumor proliferation studies.
Materials and methods
Origin of cell lines. Tumor cell lines were established from 
carcinomatous ascites of three patients with advanced GC 
diagnosed at the First Department of General Gastrointestinal 
and Oncology Surgery of the Jagiellonian University 
Medical College (Krakow, Poland). Patients provided their 
informed, written consent in the present study. The study was 
approved by the Jagiellonian University Ethical Committee 
(KBET/491/B/2003). Ascites were harvested into sterile bottles 
with heparin, centrifuged at 110 x g for 5 min. Thereafter both 
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the cells and the ascitic fluids were collected. The ascitic fluids 
were filtered and kept at ‑80˚C until use. The cell pellet was 
resuspended (1x106 /ml) in DMEM medium with high glucose 
(Sigma‑Aldrich; Merck KGaA, Darmstadt, Germany) supple-
mented with 5% fetal bovine serum (FBS; Biowest, Nuaille, 
France), 40% of autologous ascitic fluid and 50 µg/ml genta-
mycin (Sigma‑Aldrich; Merck KGaA). When the cells started to 
grow rapidly, the ascitic fluid, after a period of gradual decrease, 
was completely withdrawn from the culture. The cells were 
incubated at 37˚C in 5% CO2 atmosphere and regularly tested 
for Mycoplasma sp. contamination by PCR‑ELISA kit (Roche, 
Mannheim, Germany) and for endotoxin contamination by the 
Limulus test (Charles River Laboratories, Wilmington, MA, 
USA) according to manufacturer's instruction.
For analysis of cellular morphology, an inverted 
phase‑contrast microscope (Olympus, Tokyo, Japan) was used.
Doubling time (growth curves). Cells (1x105 /ml) in medium 
supplemented with 5% FBS and 50 µg/ml gentamycin (further 
referred as complete medium) were seeded in duplicates into 
24‑well plates (BD Falcon, Franklin Lakes, NY, USA). Every 
24 h, over a period of 5 days, cells were harvested and counted. 
The doubling time was estimated from the growth curves 
during the exponential phase of cells' growth.
Karyotyping analysis. The dividing cells, at the exponential 
growth phase (after 18 or 24 h), were exposed to the colcemid 
solution (0,25 µg/ml culture medium; Gibco; Thermo Fisher 
Scientific, Inc., Waltham, MA, USA) for 30 min. Then, the 
cells were transferred into 10 ml conical centrifuge tubes 
and centrifuged at 400 x g for 10 min, after which the super-
natant was removed and cells were suspended in 8-9 ml of 
prewarmed (37˚C) hypotonic solution (20 mM potassium 
chloride (KCl) and 10 mM sodium citrate (Na3C6H5O7; POCH 
S.A., Gliwice, Poland) with simultaneous vortexing. Next, the 
cells were incubated at 37˚C for 30 min and centrifuged at 
400 x g for 10 min. The supernatant was removed without 
disrupting the pellets and cells were suspended in 8-9 ml cold 
(4˚C) fixative solution 3:1 (methanol:glacial acetic acid ratio) 
again with simultaneous vortexing. The fixation was repeated 
3 times. Finally, cells were resuspended in 1‑2 ml of fixative 
solution and about 0,3 ml was dropped on a microscopic slide. 
The spread slides were dried for at least overnight at 37˚C 
until staining. The G‑banding was used as the routine cyto-
genetic technique. The metaphase chromosome staining was 
performed with gentle digestion in the trypsin solution [0,25% 
in 1X phosphate-buffered saline (PBS), POCH S.A.] and the 
Giemsa stain (Sigma‑Aldrich; Merck KGaA). The karyotypes 
for gastric adenocarcinoma cell lines were analyzed with the 
OLYMPUS BX51 microscope and the CytoVision Master 3.0 
software (Olympus) according to the 2013 ISCN international 
guidelines (12).
Immunophenotyping. The following fluorescein (FITC)-, 
allophycocyanin (APC)‑or phycoerythrin (PE)‑conjugated 
mouse anti-human monoclonal antibodies (mAbs) were 
used: Anti-CD10, -CD11a, CD11c, -CD18, -CD33, -CD40, 
-CDD44std, -CD44v5, -CD44v6, -CD54, -CD61, -CD62P, 
-CD86, -CD133, -CD206 (MR), -EGFR, -Her-2/neu, -HLA-DR, 
HLA class I, -CCR5, -CCR6, Her-2/neu all from BD Pharmingen 
(San Diego, CA, USA); anti‑CD29, ‑CD36, ‑CD51, ‑CD58 
from Immunotech (Marseille, France); anti‑c‑MET, ‑CCR1, 
-CCR2, -CCR3, -CCR7, -CXCR1, -CXCR2, -CXCR4 from 
R&D (Abington, UK); anti‑Tag72, ‑Mucin1 (EMA, CD227), 
‑EMMPRIN from Santa Cruz Biotechnology, Inc. (Santa Cruz, 
CA, USA) and anti-Epithelial Antigen, -Epithelial Membrane 
Antigen (EMA) from DAKO (Heverlee, Belgium). Isotype 
controls included appropriate FITC-, APC- or PE-labeled 
mouse IgG1, IgG2a or IgG2b. Cells were incubated with mAbs or 
isotype controls for 20 min at 4˚C, washed, resuspended in PBS 
and analyzed by flow cytometry (FACS Canto; BD Biosciences 
Immunocytometry Systems, San Jose, CA, USA) using FACS 
DiVa software.
Western blotting. Cells were lysed in M‑PER lysing buffer 
(Pierce; Thermo Fisher Scientific, Inc.) containing protease 
inhibitor cocktail (Roche). 20 µg of isolated protein was 
mixed with NuPAGE LDS Sample Buffer (4X; Thermo 
Fisher Scientific, Inc.) and NuPAGE Sample Reducing Agent 
(10X; Thermo Fisher Scientific, Inc.). Samples were heated 
(70˚C, 10 min) and electrophoresed in 14% polyacrylamide 
gel containing SDS (Bio-Rad, Hercules, CA, USA). Next, 
electrophoresed samples were transferred onto the polyvi-
nylidene fluoride membrane (Bio‑Rad). Then, after blocking 
for 1 h at room temperature in Tris buffered saline (TBS) 
with 0,1% Tween‑20 (Sigma‑Aldrich; Merck KGaA) and 1% 
bovine serum albumin (BSA; Sigma‑Aldrich; Merck KGaA), 
the membranes were incubated overnight at 4˚C with the 
following antibodies: Goat anti-human ALDH1A1 (clone 
L-15), ALDH1A2 (clone N-20), ALDH1A3 (clone C-13), 
ALDH2 (clone N-14) and mouse anti-human ALDH3A1 (clone 
B-8), rabbit anti-EMMPRIN (clone N-19), -panCEA (clone: 
H-300), -MAGE-A1 (clone: FL-309) and -GAPDH (clone: 
14C10) (all Santa Cruz Biotechnology, Dallas, TX, USA). As 
a loading control, rabbit anti-human GAPDH (Cell Signaling 
Technology, Inc., Danvers, MA, USA) was used. After incuba-
tion, membranes were washed in TBS supplemented with BSA 
and Tween-20 and incubated for 1 h at room temperature with 
either goat anti-rabbit or goat anti-mouse (dilution 1:4,000) 
secondary antibody conjugated with horseradish peroxidase 
(Santa Cruz Biotechnology, Inc.). The protein bands were visu-
alized with the SuperSignal West Pico Chemiluminescence 
Substrate kit according to the manufacturer's protocol (Pierce; 
Thermo Fisher Scientific, Inc.) and analyzed with KODAK 
GEL LOGIC 1500 Digital Imaging System (KODAK, 
Rochester, NY, USA).
Detection of ALDH activity. The ALDEFLUOR kit 
(StemCells Technologies, Grenoble, France) was used for iden-
tification of cells with ALDH activity. Cells were incubated 
(45 min, 37˚C, final concentration 1x106 /ml) with the Assay 
Buffer containing BODIPY‑amino‑acetaldehyde (BAAA; 
final concentration 1 µM)‑a fluorescent substrate for ALDH. 
Cells able to process the BAAA substrate to its fluorescent 
form, BODIPY-aminoacetate (BAA), were considered as 
ALDH positive (ALDH+). To confirm specificity of ALDH 
depended reaction cells were additionally incubated with 
specific ALDH inhibitor, diethylaminobenzaldehyde (DEAB). 
Cells incubated with DEAB only served as a negative control. 
After treatment, cells were washed and suspended in ice-cold 
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PBS supplemented with 0.5% of BSA and verapamil (50 µM; 
Sigma‑Aldrich; Merck KGaA) to block Abcg2 transporters 
activity and prevent active efflux of the ALDEFLUOR product 
from viable cells.
Determination of Her‑2/neu and MAGE‑1, ‑2 mRNA expres‑
sion in the cell lines using nested quantitative PCR (qPCR). 
The isolation of total RNA and qPCR for MAGE-1, -2 and 
β‑actin was performed as previously described (13). For 
detection of HER-2/neu mRNA qPCR was performed using 
the following primers: Sense-5'-CCT CTG ACG TCC ATC ATC 
TC-3' and antisense-5'-ATC TTC TCG TGC CGT CGC TT-3'. 
The cycle profile for HER‑2/neu PCR run was: Initial denatur-
ation at 95˚C for 10 min, then denaturation at 95˚C for 0 sec, 
annealing at 60˚C for 35 sec, and elongation at 72˚C for 35 sec 
for 35 cycles, followed by final extension at 72˚C for 2 min. The 
results were normalized with β-actin data and expressed as CT. 
To verify amplified product, melting curve analysis using the 
LightCycler software was performed for each sample.
Xenografts in non‑obese diabetic/severe combined immu‑
nodeficiency (NOD/SCID) mice. Cells (1x106 of each cell 
line, viability over 95%) suspended in 200 µl of saline were 
injected subcutaneously (s.c.) into dorsal region of 8-week 
old NOD/SCID mice (5 mice per group; Charles River 
Laboratories, Sulzfeld, Germany). Every three days, tumor's 
diameter was measured with a caliper and its volume (v) 
was calculated according to the formula: v=ab2/2, where 
a is the longest dimension, b is the perpendicular width. 
When moribund, the tissues were examined macroscopi-
cally for metastasis in various organs and then processed 
for histological examination (14). The study was approved 
by the Ist Local Ethical Committee on Animal Testing 
(no. 128/2012).
Histological analysis. Subcutaneous GC1401, GC1415 and 
GC1436 tumors in NOD/SCID mice and other organs (spleen, 
liver, lung, lymph nodes) of tumor‑bearing mice were cut 
out, divided into several portions and fixed in 10% buffered 
formalin. Some of them, after routine processing, were 
embedded in paraffin. 3 µm thick sections were stained with 
H&E according to manufacturer's protocol.
Statistical analysis. The non parametric Kruskal‑Wallis test 
was performed using GraphPad InStat version 4.0 software 
(GraphPad Software, Inc., La Jolla, CA, USA). P<0.05 was 
considered to indicate a statistically significant difference.
Table I. Patients' characteristics.
Cells Age Gender Stage (TNM) Histology
GC1401 72 F IV (T4NXM1) Adenocarcinoma
GC1415 73 M IV (T4NXM1) Tubular adenocarcinoma combined with signet ring
    cell carcinoma
GC1436 19 F IV (T4NXM1) Mucinous adenocarcinoma
F, female; M, Male.
Figure 2. Phase‑contrast photomicrographs of monolayers of (A) GC1401, 
(B) GC1415 and (C) GC1436 cell lines. Original magnification x400.
Figure 1. Growth curves of GC1401, GC1415 and GC1436 cell lines. Cells 
were cultured in duplicates and counted every 24 h. The differences in 
doubling time were not statistically significant.
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Results
Growth characteristics. The cells were obtained from 
carcinomatous ascites of patients diagnosed with gastric 
adenocarcinoma (Table I). All patients were evaluated as 
non-resectable, with peritoneal spread and no liver or lung 
metastases.
At the initiation of the culture, some of the cells adhered 
to the plastic surface, while the others did not. In the case of 
GC1401 and GC1415 cells, negligible proliferation of tumor 
cells was observed for several (6-8) weeks, instead, the prolif-
eration of fibroblasts was seen. After this period of adaptation 
to the in vitro conditions, both GC1401 and GC1415 cells 
started to grow rapidly. In contrast, the GC1436 cells were 
rapidly growing from the beginning. With successive passages, 
the number of fibroblasts gradually decreased, to be finally 
replaced by tumor cells. Doubling time, estimated at exponen-
tial phase of growth, for GC1401 and GC1415 cell lines was 
about 30 and 34 h, respectively, and about 25 h for GC1436 
cells (Fig. 1). The differences in doubling time were not signifi-
cant. All cells exhibited morphologic features of epithelial-like 
cells, creating the sheets of polygonal cells which attached to 
the culture flask and formed monolayer at confluence (Fig. 2).
Karyotyping. Karyotyping analysis showed a great complexity 
of all three gastric adenocarcinoma cell lines. The identified 
variety involves especially structural chromosomal aber-
rations. Additionally, high hyperdiploidy of tumor cell lines 
were detected; from 51‑56 and 52 chromosomes for GC1415 
and GC1401 to 91-106 chromosomes for GC1436. The best 
cytogenetic characterization was done for the GC1401 cell line, 
because of the presence of only two subclones (Table II). The 
karyotype description according to the international guide-
lines was also possible for this cell line. The exact result for the 
GC1436 cell line was not allowed due to high heterogeneity of 
the cells and a low resolution of the karyotype. Additionally, 
several structural and numerical chromosomal abnormalities 
were evident in all cell lines (Table III).
Expression of surface determinants. The expression of surface 
determinants on cells from in vitro cultures was evaluated 
using a wide range of mAbs (Table IV). All three cell lines 
showed a similar pattern of surface determinants with similar 
levels of expression. All cell lines were HLA-class I posi-
tive (100% of cells) and HLA‑DR negative. CD29 and CD51 
integrins and CD58 of the Ig superfamily were expressed on 
all cells. The majority of GC1401, GC1415 and GC1436 cells 
possessed the expression of CD10, CD40, CD44 and CD61 
determinants. There were differences between the cell lines in 
the expression of CD44 variants. The lowest level of v5 and v6 
was noticed on GC1401 cells (about 3 and 34%, respectively). 
GC1415 cells were positive in ~10% for the v5 and in ~50% 
Table III. Common chromosomal aberrations in gastric adenocarcinoma cell lines.
Cell lines GC1401 GC1415 GC1436
Ploidy  52 chromosomes 51‑56 chromosomes 91‑106 chromosomes
Chromosomal aberrations +der(1)t(1;17?)(p13;q11.2?) +der(1)t(1;17?)(p13;q11.2?) +der(1)t(1;17?)(p13;q11.2?)
 dup(1)(p13p32)  dup(1)(p13p32)
 +2 +2 
 der(6)t(6;17?)(p12;q11.2?) der(6)t(6;17?)(p12;q11.2?) der(6)t(6;17?)(p12;q11.2?)
 +der(10)t(10;18?)(p11.2;p11.2?)  der(10)t(10;18?)(p11.2;p11.2?)
  der(12)?add(12)(p13) der(12)?add(12)(p13)
 der(12)t(12;14?)(q22;q22?)  der(12)t(12;14?)(q22;q22?)
 ?dup(14)(q13q24) ?dup(14)(q13q24) ?dup(14)(q13q24)
 der(15)t(15;21?)(p13;q11.2?) der(15)t(15;21?)(p13;q11.2?) 
 der(19)?add(19)(p13.3)  der(19)?add(19)(p13.3)
 rob(21;21)(q10;q10) rob(21;21)(q10;q10) rob(21;21)(q10;q10)
Table II. Karyotypes of gastric adenocarcinoma cell lines.
Cell lines Karyotype (ISCN 2013)
GC1401 52,X,+der(1)t(1;17?)(p13;q11.2?),dup(1)(p13p32),+2,der(6)t(6;17?)(p12;q11.2?),+der(7)t(7;?)(p11.2;?)?add(7) 
 (q32?),+der(10)t(10;18?)(p11.2;p11.2?),der(12)t(12;14?)(q22;q22?),?dup(14)(q13q24),der(15)t(15;21?)
 (p13;q11.2?),der(16)?add(16) (q22 or q24),der(19)?add(19)(p13.3),rob(21;21)(q10;q10),+2mar[11]/52,X,+der(1)
 t(1;17?)(p13;q11.2?),dup(1)(p13p32),+2,der(6) t(6;17?)(p12;q11.2?),+der(7)t(7;?)(p11.2;?)?add(7)(q32?),+der(10)
 t(10;18?)(p11.2;p11.2?),der(12)t(12;14?)(q22;q22?),‑13,?dup(14) (q13q24),der(15)t(15;21?)(p13;q11.2?),der(16)?
 add(16)(q22 or q24),der(19)?add(19)(p13.3),rob(21;21)(q10;q10),+3mar[5]
GC1415 51‑56,X,+der(1)t(1;17?)(p13;q11.2?),+2,+der(4)?(q),+5,der(6)t(6;17?)(p12;q11.2?),+7,‑8,der(12)?add(12) (p13),?
 dup(14)(q13q24),der(15)t(15;21?)(p13;q11.2?),rob(21;21)(q10;q10),+mar[cp7]
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positive for the v6. The highest level of the v5 (app. 40%) and 
the v6 (app. 60%) positive cells was among GC1436 cells. 
Less than 10% of cells were positive for CD33 and 10‑20% 
were positive for CD86. The other determinants tested (i.e., 
CD11a, c, CD18, CD36, CD54, CD62P, CD133, CD206) were 
not detected on the cells of all three cell lines.
The cells were comparably positive for CCR3 expression 
which fluctuated between 5 to 25% of positive cells and CCR6 
was present on 6‑15% of cells. Very low percent of CCR7 
(1‑2%), CXCR1 and CXCR4 (up to 5%) and the lack of CCR1, 
2, 5, and CXCR2 expression was observed on cells of all cell 
lines.
The highest level of EMMPRIN positive cells was observed 
in GC1415 cell line (up to 66%), whereas GC1401 and GC1436 
cell lines were up to 24% positive. These results corroborate 
with western blotting data where EMMPRIN was shown to 
be present in all three cell lines (Fig. 3). Mucin1 (EMA) was 
detected on a small population of GC1401, GC1415 and GC1436 
cells (below 14%). Almost all cells of the three cell lines were 
Her‑2/neu and c‑MET positive. Tag72 was detected on a very 
low percent (app. 3%) of GC1436 cells and was not present on 
GC1401 and GC1415 cells. Epithelial Antigen was detected on 
GC1415 and GC1436, however, the percentage of positive cells 
was very low (less than 9% of cells). Presence of panCEA was 
confirmed by western blotting in all tested cell lines. Expression 
of MAGE‑1 was detected by western blotting in GC1415 and 
1436 only (Fig. 3).
Expression and activity of ALDH. ALDH expression was 
assessed by western blotting. All three tested cell lines 
expressed ALDH1A3 and ALDH2 isoforms, however, none 
of them expressed ALDH1A1, ALDH1A2 and ALDH3A1 
isoforms (Fig. 4A). The ALDH activity measured by flow 
cytometry was very low (Fig. 4B); less than 1% of cells 
showed such activity. This observation is consistent with the 
data that ALDH1A1 is the main enzyme of the ALDH family 
responsible for the enzymatic activity as determined by the 
ALDEFLUOR assay.
Determination of MAGE‑1, ‑2 and Her‑2/neu mRNA expres‑
sion by nested qPCR. In all three tumor cell lines similar 
amounts of mRNA for MAGE-1, -2 and Her-2/neu were 
detected. To verify the amplified product, melting curve 
analysis was performed for each sample confirming the pres-
ence of MAGE-1 mRNA and Her-2/neu (respectively Fig. 5).
Tumorigenicity and metastasis evaluation. All three cell lines 
were tumorigenic in vivo in NOD/SCID mice. The transplan-
tation of cells from in vitro culture led usually to the formation 
of tumors in 13 of 15 mice (~82‑89%). Following s.c. injec-
tion of 1x106 tumor cells, palpable encapsulated tumors were 
observed within 3-4 weeks (Fig. 6). The differences in tumor 
growth were not statistically significant. 100% mortality was 
noticed at week 13. Fig. 7 presents hematoxylin‑eosin staining 
of the tumor sections after 8 weeks of the tumor growth in vivo. 
Histologically in all cases malignant neoplasm of epithelial 
origin was observed.
No macro- and microscopic metastasis to lungs, liver, 
peritoneum, spleen, kidneys or lymph nodes were observed.
Discussion
There are GC cell lines already established and character-
ized, however, due to the heterogeneity of cancer cells each 
newly characterized cell line may provide new data useful for 
anticancer therapy. The presented manuscript describes the 
characterization of three new cell lines established from the 
malignant ascites of Caucasian patients diagnosed with gastric 
adenocarcinoma. The use of primary tumors as a source of 
cancer cells encounters several problems, e.g., the need for 
mechanical or enzymatic disruption which often leads to cell 
Table IV. Expression of selected surface markers on gastric 
adenocarcinoma cell lines.
 GC1401 GC1415 GC1436
Surface marker  (% of cells)  (% of cells)  (% of cells)
CD10   50 70-80 80-90
CD29 100   97-100 100
CD33 1 8 9
CD40 91-99   85-100 65-85
CD44 92-97 88-93 79-83
CD44v5 3 10   41
CD44v6 24-44 38-70 48-80
CD51 100 95-99 96-99
CD58 100 89-99   92-100
CD61 90-95 87-97 97
CD86 11-20 12-17 13-18
HLA-ABC 100 100 100
CCR3 3   10 3
CCR6   6-15   10   10
CCR7 2 1-2 1
CXCR1 5 3 3
CXCR4 2-3 3-4 3
c-MET   98   97   98
Her-2/neu 63-98 92-98   98
Tag72 0 0 2-3
Epithelial Antigen 0 4-7 2-9
Mucin1(CD227) 2-4 4-7   5-14
EMMPRIN   7-17 26-66 16-24
CD11a, CD11c, CD18, CXCR2, CCR1, CCR2, CCR5, CD206, 
HLA-DR, CD133, CD62P, CD54, CD36 were not detected.
Figure 3. Expression of EMMPRIN, panCEA and MAGE-A1 in gastric cell 
line detected by Western blotting. 1‑GC1401, 2‑GC1415 and 3‑GC1436. 
Lane 1, GC1401; lane 2, GC1415; and lane 3, GC1436.
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damage, which is not the case, when ascites is being used. Also, 
the addition of autologous ascitic fluid improves the culture 
conditions and cell survival (especially at the beginning), 
which is probably due to the presence of growth‑promoting 
factors (15). Doubling time of established cell lines fall in 
the range described for commercially available GC cell 
lines e.g., KATO, ATCC®HTB-103, ATCC®CRL-5973 and 
ATCC®CRL-5973 (21-36 h) (16).
Based on karyotyping analysis, a great cytogenetic 
complexity in the investigated cell lines was observed. 
Numerous structural and ploidy aberrations were evident in 
all three cell lines. This observation is in accordance with 
high ploidies of well-defined human stomach-derived cell 
lines in the American Type Culture Collection which are 
mostly hypotetraploid (ATCC®HTB-103, ATCC®CRL-5973, 
ATCC®CRL-5974). To the authors' best knowledge, all of the 
identified chromosomal changes are reported for the first time, 
and will be subjected to further research. It has been indicated 
that 53‑94% of advanced gastric adenocarcinomas have an 
abnormal chromosomal number (17,18). The chromosomal 
alterations have been recorded in gastric adenocarcinomas 
as gains: 1q, 3q, 7p, 7q, 8q, 9q, 10p, 11q, 13q, 17q, 19q, 20q 
and losses: 1p, 4p, 4q, 5q, 6q, 9p, 10, 13, 17p, 18q (19-25). The 
double minute chromosomes were not found in GC cell lines, 
but were described in ATCC®CRL-5971, ATCC®CRL-5973 
and ATCC®CRL‑5974 (but not KATO‑III). Additionally, 
aneuploidy has been detected as a potentially unfavorable 
prognostic marker often associated with high proliferative 
activity and metastatic potential (17,18).
A complex karyotype is often reported in aggressive 
cancers with a tendency to metastasize (26-28). The structural 
rearrangements are one of the activation modes of proto-
oncogenes and may also be a reason for suppressor genes 
inactivation, which in turn may induce and drive the neoplastic 
process. The classical karyotyping has limitations, primarily 
with the resolution of the study and the quality of metaphase 
chromosomes. Nevertheless, conventional banding remains 
the best technique for the evaluation balanced aberrations.
The phenotype analysis revealed the presence of HLA 
class I, CD40 (member of TNFR superfamily) and some 
Figure 4. Aldehyde dehydrogenase (ALDH) protein activity and expression in gastric cancer (GC) cell lines. (A) Western blot analysis was used to compare the 
expression of different ALDH isozymes GC1401 (lane 1), GC1415 (lane 2) and GC1436 (lane 3) GC cell lines. GAPDH served as loading control. (B) ALDH 
activity in GC cell lines. Flow cytometric graphs show the fluorescence intensity of reacted ALDH substrate in the absence and presence of diethylaminoben-
zaldehyde (DEAB), a specific ALDH inhibitor. Gated regions indicated ALDH+ cells.
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adhesion molecules of the Ig superfamily (CD58), integrins 
(CD29, CD51, CD61) and CD44 on almost all cells of all 
three cell lines. The level of these markers did not change 
throughout the culture. CD44 variants 5 and 6 were also 
Figure 5. Expression of mRNA for tumor markers: (A) Her-2/neu and (B) MAGE-1 in GC1401 (1), GC1415 (2), GC1436 (3) tumor cells. Negative control is out 
of scale. One representative experiment of 3 performed is presented.
Figure 6. Tumor growth of GC1401, GC1415 and GC1436 cells in NOD/SCID 
mice. Tumor volume was calculated every 3 days and presented in time rela-
tion. One experiment of two performed is shown. The observed differences 
were not statistically significant. NOD/SCID, non‑obese diabetic/severe 
combined immunodeficiency.
Figure 7. Subcutaneous injection of GC cells into NOD/SCID mice led to 
primary tumor development at the site of injection. Histological analysis of 
section stained with hematoxylin and eosin of tumor established in NOD/SCID 
is presented (A) GC1401, (B) GC1415 and (C) GC1436. Magnification x200. 
NOD/SCID, non‑obese diabetic/severe combined immunodeficiency.
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present, but their expression has varied in the course of 
culture. These markers were already detected in solid tumors 
including GC as well as GC cell lines (e.g., KATO-III, SNU-5, 
SNU-16) (29,30). Their high expression was observed in more 
expanding tumors (31) and was correlated with decreased 
patients' survival (32-35).
Among chemokine receptors, CCR3, CCR6, CCR7, 
CXCR1 and CXCR4 were present at very low levels on the 
cells of all cell lines. Chemokine receptors are involved in 
different activities of tumor cells such as migration, invasion 
and adhesion and their high levels are usually associated with 
an aggressive character of tumor cells. The presence of the 
above receptors was described on different cancer cells of the 
gastrointestinal duct, including GC (36,37), and they were 
usually upregulated during metastasis (38-42).
The level of mucin‑positive cells was low (3% of GC1401, 
5% of GC1415 and 10% of GC1436). At the same time CD10 
expression was relatively high and varied from 50% in 
GC1401 to 80% in GC1415 and up to 90% in GC1436 cells. 
Previously, expression of CD10 was observed in KATO‑III 
cell line (43). Recently, combined expression of CD10 and 
MUC was employed to distinguished between gastric and an 
intestinal types of GC (44,45). According to this classifica-
tion, the expression of CD10 and the absence of MUC-1 (or 
other proteins from MUC family) may suggest intestinal type 
of GC. Moreover, expression of c‑MET and Her‑2 may also 
confirm this histological type (46). c-MET and Her-2/neu, the 
members of receptor tyrosine kinase family, involved in tumor 
growth and survival, were present on all cells of each cell 
line, as detected at both the protein and mRNA level. Their 
overexpression is usually associated with tumor metastasis 
and poor prognosis (47,48). Strong expression of EMMPRIN 
as described by Zheng et al (49), may contribute to enhanced 
growth, invasion and angiogenesis of gastric carcinoma. New, 
EMMPRIN‑positive cell lines, may help to evaluate the angio-
genesis process.
One of the intriguing questions in this study was the lack 
of in vivo metastasis in NOD/SCID mice after subcutaneous 
engrafting of cancer cells. It has been already observed that 
although human cancer cells proliferate after injection into 
nude or SCID mice and form tumors in situ, their ability to 
form local or distal metastases is rare (50,51). In the case of the 
presented GC cell lines the lack of metastasis may have arisen 
from several reasons:
i) Heterotopic human-mice model of subcutaneous engraft-
ment of human GC in NOD/SCID mice did not reconstruct 
the conditions for growth and metastasis of human cancer in 
human microenvironment (52).
ii) Presence of a capsule may hamper metastasis (53).
iii) Low levels or lack of important agents, such as cyto-
kines/chemokines and/or their receptors (e.g., low expression 
of chemokine receptors in the case of presented GC cell lines).
iv) Lack of or very low level of cancer stem cells (CSC) 
(presented GC cell lines express CD44 but lack the expression 
of CD54 (54) or CD133+ (55) markers characteristic for CSC).
v) Very low levels of ALDH activity. The expression of 
ALDH1A3 and ALDH2 was detected by western blotting 
assay, but surprisingly very low amount of cells (app. 1%) 
exhibiting ALDH activity, as judged by the ALDEFLUOR 
assay, were observed. This may be due to the lack of ALDH1A1 
and ALDH1A2 which are potentially major contributors of 
ALDH1 activity in different types of cancer e.g., breast and 
lung cancer (56,57).
Many studies have shown elevated expression of ALDH 
isoforms other than ALDH1A1, but they do not directly 
prove that they are the cause of ALDEFLUOR activity in 
cancers (58-61).
The role of the ALDH1A3 isoform in GC progression 
still needs to be elucidated. High levels of this protein were 
observed in normal stomach tissue, however, its mRNA 
overexpression was detected in patients with GC, and was 
correlated with worse patient survival (62). ALDH2 is consti-
tutively expressed in a variety of tissues (63), however, its 
role in tumor progression is limited to genetic polymorphism 
(rs671) and correlated with alcohol consumption (64). Our data 
may suggest that the low, but noticeable, activity of ALDH 
may come from ALDH1A3 or ALDH2 isoforms, which may 
play a role in tumorigenesis in a tissue‑specific manner.
In summary, cancer metastasis is a complicated, multi‑step 
process, influenced by many factors. Despite the presence of 
some prometastatic determinants (eg. CD29, CD40, CD44, 
c‑MET, Her‑2/neu, composed karyotype) and soluble factors 
such as IL‑8, VEGF (data not shown), the lack of others 
(chemokine receptors, insufficient levels of CSC, activity of 
ALDH1A1) may disrupt the progression of metastasis leading 
to its inhibition.
The mortality of GC is very high due to its high heteroge-
neity even within the same tumor where cell subpopulations 
may show a diverse potential to growth and metastasis. In 
consequence, conventional therapies are not fully effective, as 
subpopulations of cells may differ in response to them. Three 
novel cell lines, established and characterized in our laboratory, 
may provide models for studies on biological heterogeneity of 
human GC cells.
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